Insights Into B Cells And Hiv-Specific B-Cell Responses In Hiv-Infected Individuals

Immunological Reviews

Volumn 254, Issue 1, 2013, Pages 207-224

  Moir, Susan ^a   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

B cells; Differentiation; HIV; Immune activation; Memory

Indexed keywords

B LYMPHOCYTE RECEPTOR; CD19 ANTIGEN; CD24 ANTIGEN; CD27 ANTIGEN; CD38 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; COMPLEMENT COMPONENT C3D RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FC RECEPTOR; HERMES ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN D; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN M; INTERFERON; INTERLEUKIN 15; INTERLEUKIN 7; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BONE MARROW TRANSPLANTATION; BYSTANDER EFFECT; CD4 LYMPHOCYTE COUNT; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL DIVISION; CELL PROLIFERATION; CELL SURVIVAL; CYTOKINE STORM; DISEASE COURSE; DNA MICROARRAY; DOWN REGULATION; FLOW CYTOMETRY; GENE OVEREXPRESSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERGAMMAGLOBULINEMIA; IMMUNE RESPONSE; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOPATHOGENESIS; LYMPHOCYTE SUBPOPULATION; LYMPHOCYTIC CHORIOMENINGITIS; LYMPHOID TISSUE; MEMORY CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PLASMA CELL; PRE B LYMPHOCYTE; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; SINGLE CELL ANALYSIS; SOMATIC MUTATION; T LYMPHOCYTE ACTIVATION; VIREMIA; VIRUS REPLICATION;

ANIMALS; B-LYMPHOCYTE SUBSETS; EPITOPES, B-LYMPHOCYTE; HIV; HIV INFECTIONS; HUMANS; LYMPHOID TISSUE; VIREMIA;

EID: 84879284427     PISSN: 01052896     EISSN: 1600065X     Source Type: Journal    
DOI: 10.1111/imr.12067     Document Type: Article

References (183)

1. Barre-Sinoussi F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868-871.
2. Klatzmann D, et al. Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science 1984;225:59-63.
3. Lane HC, Masur H, Edgar LC, Whalen G, Rook AH, Fauci AS. Abnormalities of B-cell activation and immunoregulation in patients with the acquired immunodeficiency syndrome. N Engl J Med 1983;309:453-458.
4. Morbach H, Eichhorn EM, Liese JG, Girschick HJ. Reference values for B cell subpopulations from infancy to adulthood. Clin Exp Immunol 2010;162:271-279.
5. Ghosh S, et al. Memory B cell function in HIV-infected children-decreased memory B cells despite ART. Pediatr Res 2009;66:185-190.
6. Klein U, Rajewsky K, Kuppers R. Human immunoglobulin (Ig)M+IgD+ peripheral blood B cells expressing the CD27 cell surface antigen carry somatically mutated variable region genes: CD27 as a general marker for somatically mutated (memory) B cells. J Exp Med 1998;188:1679-1689.
7. Malaspina A, et al. CpG oligonucleotides enhance proliferative and effector responses of B Cells in HIV-infected individuals. J Immunol 2008;181:1199-1206.
8. Moir S, et al. Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease. J Infect Dis 2008;197:572-579.
9. Moir S, et al. B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 2010;116:5571-5579.
10. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood 2005;105:4390-4398.
11. Meffre E, et al. Circulating human B cells that express surrogate light chains and edited receptors. Nat Immunol 2000;1:207-213.
12. Loder F, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med 1999;190:75-89.
13. Cuss AK, et al. Expansion of functionally immature transitional B cells is associated with human-immunodeficient states characterized by impaired humoral immunity. J Immunol 2006;176:1506-1516.
14. Ho J, et al. Two overrepresented B cell populations in HIV-infected individuals undergo apoptosis by different mechanisms. Proc Natl Acad Sci USA 2006;103:19436-19441.
15. Suryani S, et al. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood 2010;115:519-529.
16. Malaspina A, et al. Appearance of immature/transitional B cells in HIV-infected individuals with advanced disease: correlation with increased IL-7. Proc Natl Acad Sci USA 2006;103:2262-2267.
17. Moir S, et al. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc Natl Acad Sci USA 2001;98:10362-10367.
18. Moir S, et al. Decreased survival of B cells of HIV-viremic patients mediated by altered expression of receptors of the TNF superfamily. J Exp Med 2004;200:587-599.
19. Malaspina A, et al. Compromised B cell responses to influenza vaccination in HIV-infected individuals. J Infect Dis 2005;191:1442-1450.
20. Martinez-Maza O, Crabb E, Mitsuyasu RT, Fahey JL, Giorgi JV. Infection with the human immunodeficiency virus (HIV) is associated with an in vivo increase in B lymphocyte activation and immaturity. J Immunol 1987;138:3720-3724.
21. Fry TJ, et al. A potential role for interleukin-7 in T-cell homeostasis. Blood 2001;97:2983-2990.
22. Napolitano LA, et al. Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med 2001;7:73-79.
23. Malaspina A, et al. Idiopathic CD4+ T lymphocytopenia is associated with increases in immature/transitional B cells and serum levels of IL-7. Blood 2007;109:2086-2088.
24. Sereti I, et al. IL-7 administration drives T cell-cycle entry and expansion in HIV-1 infection. Blood 2009;113:6304-6314.
25. Levy Y, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest 2009;119:997-1007.
26. Lundstrom W, Fewkes NM, Mackall CL. IL-7 in human health and disease. Semin Immunol 2012;24:218-224.
27. Cagigi A, et al. The impact of active HIV-1 replication on the physiological age-related decline of immature-transitional B-cells in HIV-1 infected children. AIDS 2010;24:2075-2080.
28. Rethi B, et al. Concerted effect of lymphopenia, viraemia and T-cell activation on Fas expression of peripheral B cells in HIV-1-infected patients. AIDS 2013;27:155-162.
29. Pensieroso S, et al. B-cell subset alterations and correlated factors in HIV-1 infection. AIDS 2013; doi: 10.1097/QAD.0b013e32835edc47
30. Johannesson TG, et al. The impact of B-cell perturbations on pneumococcal conjugate vaccine response in HIV-infected adults. PLoS ONE 2012;7:e42307.
31. Tangye SG, Liu YJ, Aversa G, Phillips JH, de Vries JE. Identification of functional human splenic memory B cells by expression of CD148 and CD27. J Exp Med 1998;188:1691-1703.
32. Moir S, Fauci AS. B cells in HIV infection and disease. Nat Rev Immunol 2009;9:235-245.
33. Cagigi A, Nilsson A, Pensieroso S, Chiodi F. Dysfunctional B-cell responses during HIV-1 infection: implication for influenza vaccination and highly active antiretroviral therapy. Lancet Infect Dis 2010;10:499-503.
34. Hart M, et al. Loss of discrete memory B cell subsets is associated with impaired immunization responses in HIV-1 infection and may be a risk factor for invasive pneumococcal disease. J Immunol 2007;178:8212-8220.
35. Kruetzmann S, et al. Human immunoglobulin M memory B cells controlling Streptococcus pneumoniae infections are generated in the spleen. J Exp Med 2003;197:939-945.
36. Berkowska MA, et al. Human memory B cells originate from three distinct germinal center-dependent and -independent maturation pathways. Blood 2011;118:2150-2158.
37. Wu YC, Kipling D, Dunn-Walters DK. The relationship between CD27 negative and positive B cell populations in human peripheral blood. Front Immunol 2011;2:81.
38. Moir S, et al. Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals. J Exp Med 2008;205:1797-1805.
39. Good KL, Avery DT, Tangye SG. Resting human memory B cells are intrinsically programmed for enhanced survival and responsiveness to diverse stimuli compared to naive B cells. J Immunol 2009;182:890-901.
40. Ehrhardt GR, et al. Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. J Exp Med 2005;202:783-791.
41. Odorizzi PM, Wherry EJ. Inhibitory receptors on lymphocytes: insights from infections. J Immunol 2012;188:2957-2965.
42. Ruffin N, Thang PH, Rethi B, Nilsson A, Chiodi F. The impact of inflammation and immune activation on B cell differentiation during HIV-1 infection. Front Immunol 2011;2:90.
43. Perez-Andres M, et al. Human peripheral blood B-cell compartments: a crossroad in B-cell traffic. Cytometry B Clin Cytom 2010;78(Suppl):S47-S60.
44. Warter L, Appanna R, Fink K. Human poly- and cross-reactive anti-viral antibodies and their impact on protection and pathology. Immunol Res 2012;53:148-161.
45. Di Niro R, et al. Rapid generation of rotavirus-specific human monoclonal antibodies from small-intestinal mucosa. J Immunol 2010;185:5377-5383.
46. Buckner CM, Kardava L, Moir S. Evaluation of B Cell Function in Patients with HIV. Curr Protoc Immunol 2013; Chapter 12: Unit 12.13.
47. van Zelm MC, Szczepanski T, van der Burg M, van Dongen JJ. Replication history of B lymphocytes reveals homeostatic proliferation and extensive antigen-induced B cell expansion. J Exp Med 2007;204:645-655.
48. Titanji K, et al. Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. J Clin Invest 2010;120:3878-3890.
49. Demberg T, et al. Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J Virol 2012;86:12591-12604.
50. Velu V, et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009;458:206-210.
51. Boliar S, et al. B-lymphocyte dysfunction in chronic HIV-1 infection does not prevent cross-clade neutralization breadth. J Virol 2012;86:8031-8040.
52. Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G. Natural SIV hosts: showing AIDS the door. Science 2012;335:1188-1193.
53. Sodora DL, et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med 2009;15:861-865.
54. Kaur A, et al. Dynamics of T- and B-lymphocyte turnover in a natural host of simian immunodeficiency virus. J Virol 2008;82:1084-1093.
55. Haddad EK, Hiscott J. Cytokine networks during HIV infection: shifting the balance. Cytokine Growth Factor Rev 2012;23:139-141.
56. Klasse PJ, Sanders RW, Cerutti A, Moore JP. How can HIV-type-1-Env immunogenicity be improved to facilitate antibody-based vaccine development? AIDS Res Hum Retroviruses 2012;28:1-15.
57. Quaranta MG, Mattioli B, Giordani L, Viora M. Immunoregulatory effects of HIV-1 Nef protein. BioFactors 2009;35:169-174.
58. Regidor DL, et al. Effect of highly active antiretroviral therapy on biomarkers of B-lymphocyte activation and inflammation. AIDS 2011;25:303-314.
59. Kekow J, Hobusch G, Gross WL. Predominance of the IgG1 subclass in the hypergammaglobulinemia observed in pre-AIDS and AIDS. Cancer Detect Prev 1988;12:211-216.
60. Muller F, Froland SS, Brandtzaeg P. Altered IgG-subclass distribution in lymph node cells and serum of adults infected with human immunodeficiency virus (HIV). Clin Exp Immunol 1989;78:153-158.
61. Nixon DE, Landay AL. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS 2010;5:498-503.
62. Mir KD, Mavigner M, Silvestri G. The myeloid cytokine network in AIDS pathogenesis. Cytokine Growth Factor Rev 2012;23:223-231.
63. Nimmerjahn F, Ravetch JV. Antibody-mediated modulation of immune responses. Immunol Rev 2010;236:265-275.
64. Cohen MS, Shaw GM, McMichael AJ, Haynes BF. Acute HIV-1 Infection. N Engl J Med 2011;364:1943-1954.
65. Stacey AR, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol 2009;83:3719-3733.
66. Roberts L, et al. Plasma cytokine levels during acute HIV-1 infection predict HIV disease progression. AIDS 2010;24:819-831.
67. Gay C, et al. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS ONE 2011;6:e19617.
68. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298:2199-2202.
69. Perrier C, et al. Interleukin-15 receptor alpha expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab. Immunology 2013;138:47-56.
70. Cerutti A, Puga I, Cols M. Innate control of B cell responses. Trends Immunol 2011;32:202-211.
71. Stylianou E, et al. Effects of interferon-alpha on gene expression of chemokines and members of the tumour necrosis factor superfamily in HIV-infected patients. Clin Exp Immunol 2002;130:279-285.
72. Mauri C, Bosma A. Immune regulatory function of B cells. Annu Rev Immunol 2012;30:221-241.
73. Rousset F, et al. Interleukin 10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA 1992;89:1890-1893.
74. Barber DL, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006;439:682-687.
75. Day CL, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006;443:350-354.
76. Trautmann L, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med 2006;12:1198-1202.
77. Petrovas C, et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J Exp Med 2006;203:2281-2292.
78. Kaufmann DE, et al. Upregulation of CTLA-4 by HIV-specific CD4(+) T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol 2007;8:1246-1254.
79. Jones RB, et al. Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection. J Exp Med 2008;205:2763-2779.
80. Wherry EJ, et al. Molecular Signature of CD8(+) T Cell Exhaustion during Chronic Viral Infection. Immunity 2007;27:670-684.
81. Charles ED, et al. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 2011;117:5425-5437.
82. Illingworth J, et al. Chronic exposure to Plasmodium falciparum is associated with phenotypic evidence of B and T cell exhaustion. J Immunol 2013;190:1038-1047.
83. Muellenbeck MF, et al. Atypical and classical memory B cells produce Plasmodium falciparum neutralizing antibodies. J Exp Med 2013;210:389-399.
84. Isnardi I, et al. Complement receptor 2/CD21- human naive B cells contain mostly autoreactive unresponsive clones. Blood 2010;115:5026-5036.
85. Saadoun D, et al. Expansion of autoreactive unresponsive CD21(-/low) B cells in Sjogren's syndrome associated lymphoproliferation. Arthritis Rheum 2012; doi: 10.1002/art.37828
86. Kardava L, et al. Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors. J Clin Invest 2011;121:2614-2624.
87. Sohn HW, Krueger PD, Davis RS, Pierce SK. FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling. Blood 2011;118:6332-6341.
88. Morris L, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998;188:233-245.
89. De Milito A, et al. Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection. Blood 2004;103:2180-2186.
90. Fournier AM, et al. Dynamics of spontaneous HIV-1 specific and non-specific B-cell responses in patients receiving antiretroviral therapy. AIDS 2002;16:1755-1760.
91. Levesque MC, et al. Polyclonal B cell differentiation and loss of gastrointestinal tract germinal centers in the earliest stages of HIV-1 infection. PLoS Med 2009;6:e1000107.
92. International ASSWGoHIVC, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol 2012;12:607-614.
93. Nagase H, et al. Mechanism of hypergammaglobulinemia by HIV infection: circulating memory B-cell reduction with plasmacytosis. Clin Immunol 2001;100:250-259.
94. Titanji K, et al. Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection. Blood 2006;108:1580-1587.
95. Titanji K, et al. Primary HIV-1 infection sets the stage for important B lymphocyte dysfunctions. AIDS 2005;19:1947-1955.
96. Pensieroso S, et al. Timing of HAART defines the integrity of memory B cells and the longevity of humoral responses in HIV-1 vertically-infected children. Proc Natl Acad Sci USA 2009;106:7939-7944.
97. Hecht FM, et al. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis 2006;194:725-733.
98. van Grevenynghe J, et al. Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest 2011;121:3877-3888.
99. Pantaleo G, et al. Role of lymphoid organs in the pathogenesis of human immunodeficiency virus (HIV) infection. Immunol Rev 1994;140:105-130.
100. Racz P, et al. Lymphatic tissue changes in AIDS and other retrovirus infections: tools and insights. Lymphology 1990;23:85-91.
101. Orenstein JM. Hyperplastic lymphoid tissue in HIV/AIDS: an electron microscopic study. Ultrastruct Pathol 2008;32:161-169.
102. Klatt NR, Funderburg NT, Brenchley JM. Microbial translocation, immune activation, and HIV disease. Trends Microbiol 2013;21:6-13.
103. Pereira JP, Kelly LM, Cyster JG. Finding the right niche: B-cell migration in the early phases of T-dependent antibody responses. Int Immunol 2010;22:413-419.
104. Oracki SA, Walker JA, Hibbs ML, Corcoran LM, Tarlinton DM. Plasma cell development and survival. Immunol Rev 2010;237:140-159.
105. Ost A, et al. Lymphadenopathy in HIV infection: histological classification and staging. APMIS Suppl 1989;8:7-15.
106. Pallesen G, Gerstoft J, Mathiesen L. Stages in LAV/HTLV-III lymphadenitis. I. Histological and immunohistological classification. Scand J Immunol 1987;25:83-91.
107. Tenner-Racz K, Racz P. Follicular dendritic cells initiate and maintain infection of the germinal centers by human immunodeficiency virus. Curr Top Microbiol Immunol 1995;201:141-159.
108. Cohen OJ, Pantaleo G, Lam GK, Fauci AS. Studies on lymphoid tissue from HIV-infected individuals: implications for the design of therapeutic strategies. Springer Semin Immunopathol 1997;18:305-322.
109. Tenner-Racz K, et al. The unenlarged lymph nodes of HIV-1-infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation. The impact of highly active antiretroviral therapy. J Exp Med 1998;187:949-959.
110. Margolin DH, et al. High frequency of virus-specific B lymphocytes in germinal centers of simian-human immunodeficiency virus-infected rhesus monkeys. J Virol 2002;76:3965-3973.
111. Kussick SJ, Kalnoski M, Braziel RM, Wood BL. Prominent clonal B-cell populations identified by flow cytometry in histologically reactive lymphoid proliferations. Am J Clin Pathol 2004;121:464-472.
112. Hong JJ, Amancha PK, Rogers K, Ansari AA, Villinger F. Spatial alterations between CD4(+) T follicular helper, B, and CD8(+) T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J Immunol 2012;188:3247-3256.
113. Fontaine J, et al. High expression levels of B lymphocyte stimulator (BLyS) by dendritic cells correlate with HIV-related B-cell disease progression in humans. Blood 2011;117:145-155.
114. Nilsson J, Kinloch-de-Loes S, Granath A, Sonnerborg A, Goh LE, Andersson J. Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. AIDS 2007;21:565-574.
115. Herbeuval JP, et al. TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells. Blood 2005;105:2458-2464.
116. Lindqvist M, et al. Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J Clin Invest 2012;122:3271-3280.
117. Petrovas C, et al. CD4 T follicular helper cell dynamics during SIV infection. J Clin Invest 2012;122:3281-3294.
118. Li Q, Gebhard K, Schacker T, Henry K, Haase AT. The relationship between tumor necrosis factor and human immunodeficiency virus gene expression in lymphoid tissue. J Virol 1997;71:7080-7082.
119. Crotty S. Follicular helper CD4 T cells (TFH). Annu Rev Immunol 2011;29:621-663.
120. Schaerli P, Willimann K, Lang AB, Lipp M, Loetscher P, Moser B. CXC chemokine receptor 5 expression defines follicular homing T cells with B cell helper function. J Exp Med 2000;192:1553-1562.
121. Breitfeld D, et al. Follicular B helper T cells express CXC chemokine receptor 5, localize to B cell follicles, and support immunoglobulin production. J Exp Med 2000;192:1545-1552.
122. Ma CS, Deenick EK, Batten M, Tangye SG. The origins, function, and regulation of T follicular helper cells. J Exp Med 2012;209:1241-1253.
123. Cannons JL, et al. Optimal germinal center responses require a multistage T cell:B cell adhesion process involving integrins, SLAM-associated protein, and CD84. Immunity 2010;32:253-265.
124. Nurieva RI, et al. Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages. Immunity 2008;29:138-149.
125. Fahey LM, Wilson EB, Elsaesser H, Fistonich CD, McGavern DB, Brooks DG. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J Exp Med 2011;208:987-999.
126. Hunziker L, et al. Hypergammaglobulinemia and autoantibody induction mechanisms in viral infections. Nat Immunol 2003;4:343-349.
127. Stellbrink HJ, et al. HIV-induced immune activation: pathogenesis and clinical relevance - summary of a workshop organized by the German AIDS Society (DAIG e.v.) and the ICH Hamburg, Hamburg, Germany, November 22, 2008. Eur J Med Res 2010;15:1-12.
128. Kaufmann DE, Walker BD. PD-1 and CTLA-4 inhibitory cosignaling pathways in HIV infection and the potential for therapeutic intervention. J Immunol 2009;182:5891-5897.
129. Johnston RJ, et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 2009;325:1006-1010.
130. Nurieva RI, et al. Bcl6 mediates the development of T follicular helper cells. Science 2009;325:1001-1005.
131. Rose ML, Birbeck MS, Wallis VJ, Forrester JA, Davies AJ. Peanut lectin binding properties of germinal centres of mouse lymphoid tissue. Nature 1980;284:364-366.
132. Perreau M, et al. Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J Exp Med 2013;210:143-156.
133. Pascual V, Liu YJ, Magalski A, de Bouteiller O, Banchereau J, Capra JD. Analysis of somatic mutation in five B cell subsets of human tonsil. J Exp Med 1994;180:329-339.
134. Xu W, et al. HIV-1 evades virus-specific IgG2 and IgA responses by targeting systemic and intestinal B cells via long-range intercellular conduits. Nat Immunol 2009;10:1008-1017.
135. Swingler S, et al. Evidence for a pathogenic determinant in HIV-1 Nef involved in B cell dysfunction in HIV/AIDS. Cell Host Microbe 2008;4:63-76.
136. Martinez-Maza O, Breen EC. B-cell activation and lymphoma in patients with HIV. Curr Opin Oncol 2002;14:528-532.
137. Shaffer AL, Rosenwald A, Staudt LM. Lymphoid malignancies: the dark side of B-cell differentiation. Nat Rev Immunol 2002;2:920-932.
138. Marchetti G, Tincati C, Silvestri G. Microbial Translocation in the Pathogenesis of HIV Infection and AIDS. Clin Microbiol Rev 2013;26:2-18.
139. Peruchon S, et al. Tissue-specific B-cell dysfunction and generalized memory B-cell loss during acute SIV infection. PLoS ONE 2009;4:e5966.
140. McMichael AJ, Borrow P, Tomaras GD, Goonetilleke N, Haynes BF. The immune response during acute HIV-1 infection: clues for vaccine development. Nat Rev Immunol 2010;10:11-23.
141. Corti D, Lanzavecchia A. Broadly Neutralizing Antiviral Antibodies. Annu Rev Immunol 2013;31:705-742.
142. Mestecky J, et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. AIDS Res Hum Retroviruses 2004;20:972-988.
143. Scamurra RW, et al. Mucosal plasma cell repertoire during HIV-1 infection. J Immunol 2002;169:4008-4016.
144. Schafer F, et al. Lack of simian immunodeficiency virus (SIV) specific IgA response in the intestine of SIV infected rhesus macaques. Gut 2002;50:608-614.
145. Schneider T, et al. Increased immunoglobulin G production by short term cultured duodenal biopsy samples from HIV infected patients. Gut 1998;42:357-361.
146. Olsson J, et al. Human immunodeficiency virus type 1 infection is associated with significant mucosal inflammation characterized by increased expression of CCR5, CXCR4, and beta-chemokines. J Infect Dis 2000;182:1625-1635.
147. Cerutti A, et al. Regulation of mucosal IgA responses: lessons from primary immunodeficiencies. Ann N Y Acad Sci 2011;1238:132-144.
148. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012;337:183-186.
149. Kwong PD, Mascola JR. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 2012;37:412-425.
150. Bonsignori M, et al. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol 2012;20:532-539.
151. Burton DR, et al. A Blueprint for HIV Vaccine Discovery. Cell Host Microbe 2012;12:396-407.
152. Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev 2013;251:177-188.
153. Fink K. Origin and function of circulating plasmablasts during acute viral infections. Front Immunol 2012;3:78.
154. Scheid JF, et al. A method for identification of HIV gp140 binding memory B cells in human blood. J Immunol Methods 2009;343:65-67.
155. Amadori A, De Rossi A, Faulkner-Valle GP, Chieco-Bianchi L. Spontaneous in vitro production of virus-specific antibody by lymphocytes from HIV-infected subjects. Clin Immunol Immunopathol 1988;46:342-351.
156. Shirai A, Cosentino M, Leitman-Klinman SF, Klinman DM. Human immunodeficiency virus infection induces both polyclonal and virus-specific B cell activation. J Clin Invest 1992;89:561-566.
157. Buckner CM, et al. Characterization of Plasmablasts in the Blood of HIV-Infected Viremic Individuals: Evidence for Non-Specific Immune Activation. J Virol 2013; doi: 10.1128/JVI.00094-13.
158. Eriksson K, Kilander A, Hagberg L, Norkrans G, Holmgren J, Czerkinsky C. Virus-specific antibody production and polyclonal B-cell activation in the intestinal mucosa of HIV-infected individuals. AIDS 1995;9:695-700.
159. Doria-Rose NA, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009;83:188-199.
160. Lee FE, Falsey AR, Halliley JL, Sanz I, Walsh EE. Circulating antibody-secreting cells during acute respiratory syncytial virus infection in adults. J Infect Dis 2010;202:1659-1666.
161. Wrammert J, et al. Rapid and massive virus-specific plasmablast responses during acute dengue virus infection in humans. J Virol 2012;86:2911-2918.
162. Wrammert J, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med 2011;208:181-193.
163. Liao HX, et al. Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated. J Exp Med 2011;208:2237-2249.
164. Burton DR, Barbas CF 3rd, Persson MA, Koenig S, Chanock RM, Lerner RA. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991;88:10134-10137.
165. Scheid JF, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011;333:1633-1637.
166. Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010;236:125-138.
167. Cerutti A, Chen K, Chorny A. Immunoglobulin responses at the mucosal interface. Annu Rev Immunol 2011;29:273-293.
168. Mestecky J. Humoral immune responses to the human immunodeficiency virus type-1 (HIV-1) in the genital tract compared to other mucosal sites. J Reprod Immunol 2007;73:86-97.
169. Shacklett BL, Greenblatt RM. Immune responses to HIV in the female reproductive tract, immunologic parallels with the gastrointestinal tract, and research implications. Am J Reprod Immunol 2011;65:230-241.
170. Bomsel M, et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 2011;34:269-280.
171. Tudor D, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis. Mucosal Immunol 2009;2:412-426.
172. Hur EM, et al. Inhibitory effect of HIV-specific neutralizing IgA on mucosal transmission of HIV in humanized mice. Blood 2012;120:4571-4582.
173. Fondere JM, et al. Detection of peripheral HIV-1-specific memory B cells in patients untreated or receiving highly active antiretroviral therapy. AIDS 2003;17:2323-2330.
174. Dosenovic P, et al. Selective expansion of HIV-1 envelope glycoprotein-specific B cell subsets recognizing distinct structural elements following immunization. J Immunol 2009;183:3373-3382.
175. Crotty S, Aubert RD, Glidewell J, Ahmed R. Tracking human antigen-specific memory B cells: a sensitive and generalized ELISPOT system. J Immunol Methods 2004;286:111-122.
176. Moir S, Malaspina A, Fauci AS. Prospects for an HIV vaccine: leading B cells down the right path. Nat Struct Mol Biol 2011;18:1317-1321.
177. Kobie JJ, et al. 9G4 autoreactivity is increased in HIV-infected patients and correlates with HIV broadly neutralizing serum activity. PLoS ONE 2012;7:e35356.
178. Scheid JF, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009;458:636-640.
179. Walker LM, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009;326:285-289.
180. Wu X, et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010;329:856-861.
181. Wu X, et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011;333:1593-1602.
182. Liao HX, et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013;38:176-186.
183. Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science 2003;301:1374-1377.